Related Experiment Video

Updated: Jul 5, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis

I Sobczak1, G Galabova-Kovacs, I Sadzak

  • 1Department of Microbiology and Immunobiology, Max F Perutz Laboratories, University of Vienna, Vienna, Austria.

Oncogene
|May 21, 2008
PubMed

Insights

B-Raf is essential for tumor growth, supporting cancer cell proliferation and blood vessel formation. Ablating B-Raf in pancreatic tumors impaired ERK activation, reduced vessel density, and hindered tumor progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The Raf/MEK/ERK pathway is frequently activated in human cancers.
  • ERK pathway activation is crucial for cancer cell proliferation, particularly with BRAF or RAS mutations.
  • The role of B-Raf in tumor development and angiogenesis in vivo, especially without specific mutations, remains unclear.

Purpose of the Study:

  • To investigate the role of endogenous B-Raf in tumor angiogenesis and progression.
  • To determine if B-Raf is required for ERK activation and angiogenic factor expression in a pancreatic cancer model.
  • To assess the impact of B-Raf ablation on tumor growth, vessel density, and overall progression.

Main Methods:

  • Conditional ablation of B-Raf in a RIP1Tag2 mouse model of pancreatic islet carcinoma.
  • Assessment of ERK activation and expression of angiogenic factors in tumor cells in vitro and in vivo.
  • Evaluation of tumor growth, vessel density, proliferation, and progression from adenoma to carcinoma.

Main Results:

  • B-Raf is dispensable for tumor cell proliferation in culture but essential for ERK activation and angiogenic factor expression.
  • Conditional ablation of B-Raf led to decreased vessel density and reduced tumor cell proliferation in vivo.
  • Tumor progression from adenoma to carcinoma was significantly impaired following B-Raf ablation.

Conclusions:

  • Endogenous B-Raf plays a critical role in supporting the stromal response and promoting tumor progression in RIP1Tag2 pancreatic tumors.
  • B-Raf is necessary for tumor angiogenesis and overall tumor development, independent of specific BRAF mutations.
  • Targeting B-Raf may represent a therapeutic strategy for inhibiting tumor growth and progression in relevant cancer types.

More Related Videos

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model06:24

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model

Published on: April 18, 2015

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...